## **SUMMARY OF PRODUCT CHARACTERISTICS**

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Drontal Dog Tasty Bone 150/144/50 mg tablets

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

### **Active substances:**

150 mg febantel 50 mg pyrantel equivalent to 144 mg pyrantel embonate 50 mg praziquantel

## **Excipients:**

Qualitative composition of excipients and other constituents		
Maize starch		
Lactose monohydrate		
Microcrystalline cellulose		
Povidone K25		
Magnesium stearate		
Sodium laurilsulfate		
Silica, colloidal anhydrous		
Croscarmellose sodium		
Meat flavour		

A light-brown to brown bone shaped tablet scored on both sides that can be divided into halves.

### 3. CLINICAL INFORMATION

## 3.1 Target species

Dogs.

## 3.2 Indications for use for each target species

Treatment of mixed infections by nematodes and cestodes of the following species:

Roundworms:

Ascarids (adult and late immature forms): Toxocara canis, Toxascaris leonina

Hookworms (adults): Uncinaria stenocephala,

Ancylostoma caninum

Whipworms (adults): Trichuris vulpis

Tapeworms (adult and immature forms): Echinococcus granulosus

Echinococcus multilocularis

Dipylidium caninum

Taenia spp.

### 3.3 Contraindications

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not use during the 1st and 2nd third of pregnancy (see section 3.7).

## 3.4 Special warnings

Fleas serve as intermediate hosts for one common type of tapeworm - *Dipylidium caninum*. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.

### 3.5 Special precautions for use

Special precautions for use in the target species:

Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

To minimise the risk of reinfestation and new infestation, excreta should be collected and properly disposed of for 24 hours following treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

In the interests of good hygiene, persons administering the product directly to a dog or by adding it to the dog's food should wash their hands afterwards.

Special precautions for the protection of the environment:

Not applicable.

### Other precautions:

Since it contains praziquantel, the product is effective against *Echinococcus* spp. which do not occur in all EU member states but are becoming more common in some. Echinococcosis represents a hazard for humans.

As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

### 3.6 Adverse events

### Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated	Digestive tract disorders (e.g., vomiting and diarrhoea) <sup>1</sup>
reports):	Anorexia, Lethargy,
	Hyperactivity.

<sup>&</sup>lt;sup>1</sup>Mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder <or its local representative> or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

## 3.7 Use during pregnancy, lactation or lay

### Pregnancy and lactation:

Teratogenic effects attributed to high doses of febantel administered during early pregnancy have been reported in rats, sheep and dogs.

The safety of the product has not been investigated during the 1st and 2nd third of pregnancy. Do not use in pregnant dogs during the 1st and 2nd third of pregnancy (see section 3.3).

A single treatment during the last third of pregnancy or during lactation has been demonstrated safe.

### 3.8 Interaction with other medicinal products and other forms of interaction

The anthelmintic effects of this product and piperazine containing products may be antagonized when the two drugs are used together.

Concurrent use with other cholinergic compounds can lead to toxicity.

### 3.9 Administration routes and dosage

For oral administration only.

### <u>Dosage</u>

For treatment of dogs, 1 tablet per 10 kg body weight (15 mg febantel, 14.4 mg pyrantel embonate and 5 mg praziquantel/kg body weight).

<u>Dosages are as follows:</u>

Body weight (kg)	Tablet quantity
2-5	1/2
>5-10	1
>10-15	1 ½
>15-20	2

For each additional 5 kg bodyweight, administer an additional half tablet.

## Administration and Duration of Treatment

The tablets are flavoured and studies have shown that they are palatable and are taken voluntarily by the majority (88%) of dogs tested.

The tablets can be administered with or without food. Access to normal diet does not need to be limited before or after treatment.

Tablets should be given as a single administration.

The advice of a veterinarian should be sought regarding the need for and frequency of repeat treatment.

Not for use in dogs weighing less than 2 kg.

To ensure a correct dosage, body weight should be determined as accurately as possible.

# 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No signs of adverse reactions were observed in safety studies in dogs and pups following administration of 10 times the recommended dose of the product.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

### 3.12 Withdrawal period

Not applicable.

### 4. PHARMACOLOGICAL INFORMATION

#### 4.1 ATCvet code:

**QP52AA51** 

### 4.2 Pharmacodynamics

The product is an anthelmintic containing as active substances the tetrahydropyrimidine derivative pyrantel (as the embonate salt), the probenzimidazole febantel and praziquantel, a partly hydrogenated pyrazinoisoquinoline derivative. It is effective against certain roundworms and tapeworms.

In this fixed combination pyrantel and febantel act synergistically against roundworms (ascarides, hookworms and whipworms) in dogs. In particular, the action spectrum covers *Toxocara canis, Toxascaris leonina, Uncinaria stenocephala, Ancylostoma caninum,* and *Trichuris vulpis*.

The spectrum of activity of praziquantel covers tapeworm species in dogs. In particular, it includes all *Taenia* species, as well as *Multiceps multiceps, Dipylidium caninum, Echinococcus granulosus* and *Echinococcus multilocularis*. Praziquantel acts against all intestinal stage of these parasites.

Pyrantel acts as the nicotine, as a cholinergic agonist, causing spastic paralysis of roundworms via a depolarising neuromuscular block.

The anthelmintic efficacy of febantel is due to its ability to inhibit the polymerisation of tubuline to microtubuli. The resulting structural and functional metabolic disturbances exhaust the parasite's energy reserves and kill it in 2-3 days.

Praziquantel is absorbed very rapidly through the parasite's surfaces and is evenly distributed throughout their bodies. It causes severe damage of their integument, leading to disruption of metabolism and thence to death.

### 4.3 Pharmacokinetics

Praziquantel is absorbed almost completely in the small intestine following oral administration to dogs. Absorption is very rapid reaching maximum serum levels within 0.5 to 2 hours. After absorption, the drug is widely distributed through the body. Plasma protein binding is high. Praziquantel is rapidly metabolized in the liver leading to inactive metabolites. In dogs, metabolites are eliminated by urine (66 % of an oral dose) and via the bile (15%) in the faeces. Elimination half-life in dogs is about 3 hours.

Pyrantel (as embonate), being a low water-soluble compound, is poorly absorbed in the gastrointestinal tract, reaching the final parts of the intestine. The absorbed drug is extensively metabolized and the parent compound/metabolites are excreted by urine.

Febantel is a pro-drug that after oral administration and oral absorption is metabolized to fenbendazole and oxfendazole, the chemical entities exerting the anthelmintic effect. The active metabolites are excreted via faeces.

### 5. PHARMACEUTICAL PARTICULARS

## 5.1 Major incompatibilities

Not applicable.

#### 5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Shelf life of half-tablets after first opening the immediate packaging: 7 days.

### 5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

After opening the blister, remaining half-tablets should be wrapped in aluminium foil and returned to the open blister for use within 7 days.

### 5.4 Nature and composition of immediate packaging

Container material: Blisters formed from PA/Alu/PE foil and sealed with Alu/PE foil.

Container sizes: Cartons containing 2, 4, 6, 24, 102, 312 tablets.

Not all pack sizes may be marketed.

# 5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

### 6. NAME OF THE MARKETING AUTHORISATION HOLDER

Vetoquinol SA

## 7. MARKETING AUTHORISATION NUMBER

Vm 06462/3018

## 8. DATE OF FIRST AUTHORISATION

21 October 2014

# 9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

July 2025

# 10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product not subject to prescription: NFA-VPS

Detailed information on this veterinary medicinal product is available in the <u>Union Product Database</u> (https://medicines.health.europa.eu/veterinary).

Gavin Hall

Approved: 10 October 2025